**Table 1. Modified Delphi Agreement Table**. Round 1 and Round 2 for Colorectal Cancer with

Synchronous and Metachronous Peritoneal Metastases. Percent agreement includes agree and

strongly agree.

**Table 1a.** Round 1 Agreement Table for Colorectal Cancer with Synchronous Peritoneal Metastases.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Strongly agree** | **Agree** | **Neither agree nor disagree** | **Disagree** | **Strongly disagree** | **Total** | **% Agree** |
| **Block 1** | 106 | 36 | 2 | 0 | 1 | 145 | 98% |
| **Block 2** | 111 | 27 | 5 | 2 | 0 | 145 | 95% |
| **Block 3** | 94 | 43 | 6 | 2 | 0 | 145 | 94% |
| **Block 4** | 67 | 45 | 20 | 13 | 0 | 145 | 77% |
| **Block 5** | 95 | 42 | 6 | 2 | 0 | 145 | 94% |
| **Block 6** | 90 | 44 | 8 | 3 | 0 | 145 | 92% |
| **Block 7** | 86 | 49 | 9 | 1 | 0 | 145 | 93% |
| **Block 8** | 69 | 50 | 17 | 9 | 0 | 145 | 82% |
| **Block 9** | 90 | 45 | 5 | 5 | 0 | 145 | 93% |
| **Block 10** | 76 | 49 | 15 | 5 | 0 | 145 | 86% |
| **Block 11** | 77 | 50 | 12 | 5 | 1 | 145 | 88% |

**Table 1b**. Round 2 Agreement Table for Colorectal Cancer with Synchronous Peritoneal Metastases.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Strongly agree** | **Agree** | **Neither agree nor disagree** | **Disagree** | **Strongly disagree** | **Total** | **% Agree** |
| **Block 1** | 123 | 12 | 0 | 1 | 0 | 136 | 99% |
| **Block 2** | 120 | 14 | 1 | 1 | 0 | 136 | 99% |
| **Block 3** | 117 | 16 | 3 | 0 | 0 | 136 | 98% |
| **Block 4** | 95 | 25 | 7 | 5 | 4 | 136 | 88% |
| **Block 5** | 123 | 11 | 1 | 0 | 1 | 136 | 99% |
| **Block 6** | 116 | 14 | 4 | 1 | 1 | 136 | 96% |
| **Block 7** | 122 | 12 | 1 | 1 | 0 | 136 | 99% |
| **Block 8** | 110 | 16 | 5 | 4 | 1 | 136 | 93% |
| **Block 9** | 117 | 14 | 3 | 1 | 1 | 136 | 96% |
| **Block 10** | 118 | 12 | 4 | 1 | 1 | 136 | 96% |
| **Block 11** | 119 | 15 | 1 | 0 | 1 | 136 | 99% |

**Table 1c**. Round 1 Agreement Table for Colorectal Cancer with Metachronous Peritoneal Metastases.\*

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Strongly agree** | **Agree** | **Neither agree nor disagree** | **Disagree** | **Strongly disagree** | **Total** | **% Agree** |
| **Block 1** | 102 | 39 | 3 | 0 | 1 | 145 | 97% |
| **Block 2** | 103 | 36 | 4 | 2 | 0 | 145 | 96% |
| **Block 3** | 93 | 43 | 7 | 2 | 0 | 145 | 94% |
| **Block 4** | 84 | 44 | 15 | 1 | 1 | 145 | 88% |
| **Block 5** | 93 | 41 | 6 | 5 | 0 | 145 | 92% |
| **Block 6** | 95 | 42 | 8 | 0 | 0 | 145 | 94% |
| **Block 7** | 98 | 35 | 10 | 2 | 0 | 145 | 92% |
| **Block 8** | 84 | 46 | 11 | 3 | 1 | 145 | 90% |
| **Block 9** | 80 | 45 | 14 | 5 | 1 | 145 | 86% |

*\*Block 10 was not subjected to consensus voting in the metachronous pathway as it was identical*

*to Block 11 in the synchronous pathway.*

**Table 1d**. Round 2 Agreement Table for Colorectal Cancer with Metachronous Peritoneal

Metastases.\*

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Strongly agree** | **Agree** | **Neither agree nor disagree** | **Disagree** | **Strongly disagree** | **Total** | **% Agree** |
| **Block 1** | 123 | 12 | 0 | 1 | 0 | 136 | 99% |
| **Block 2** | 120 | 13 | 2 | 1 | 0 | 136 | 98% |
| **Block 3** | 124 | 10 | 1 | 1 | 0 | 136 | 99% |
| **Block 4** | 118 | 17 | 1 | 0 | 0 | 136 | 99% |
| **Block 5** | 117 | 15 | 3 | 1 | 0 | 136 | 97% |
| **Block 6** | 124 | 9 | 3 | 0 | 0 | 136 | 98% |
| **Block 7** | 119 | 13 | 4 | 0 | 0 | 136 | 97% |
| **Block 8** | 117 | 13 | 3 | 2 | 1 | 136 | 96% |
| **Block 9** | 119 | 15 | 1 | 0 | 1 | 136 | 99% |

*\*Block 10 was not subjected to consensus voting in the metachronous pathway as it was identical*

*to Block 11 in the synchronous pathway.*

**Table 2.** Systemic Therapy Regimens for Metastatic Colorectal Malignancy with Peritoneal Involvement.

|  |  |  |  |
| --- | --- | --- | --- |
| Type of CRC | Stage of therapy | Initial therapy | Subsequent therapy |
| Initially unresectable pMMR/MSS mCRC, left-sided, RAS wildtype | Definitive/conversion chemotherapy | FOLFOX or FOLFIRI doublet chemotherapy ± anti-EGFR or anti-VEGF preferred \*FOLFOXIRI triplet chemotherapy (up to 12 cycles) ± anti-VEGF may be considered followed by maintenance 5-FU/leucovorin/bevacizumab | *Regimens as described at left not previously attempted* |
| Other initially unresectable pMMR/MSS mCRC | Definitive/conversion chemotherapy | FOLFOX or FOLFIRI doublet chemotherapy ± anti-VEGF preferred\*FOLFOXIRI triplet chemotherapy (up to 12 cycles) ± anti-VEGF may be considered followed by maintenance 5-FU/leucovorin/bevacizumab | *Regimens as described at left not previously attempted* |
| Complete cytoreduction predicted pMMR/MSS mCRC, left-sided, RAS wildtype | Neoadjuvant chemotherapy | FOLFOX or FOLFIRI doublet chemotherapy ± anti-EGFR or anti-VEGF preferred\*FOLFOXIRI triplet chemotherapy (up to 12 cycles) ± anti-VEGF may be considered followed by maintenance 5-FU/leucovorin/bevacizumab | *Regimens as described at left not previously attempted* |
| Complete cytoreduction predicted pMMR/MSS mCRC | Neoadjuvant chemotherapy | FOLFOX or FOLFIRI doublet chemotherapy ± anti-VEGF preferred\*FOLFOXIRI triplet chemotherapy (up to 12 cycles) ± anti-VEGF may be considered followed by maintenance 5-FU/leucovorin/bevacizumab | *Regimens as described at left not previously attempted* |
| dMMR/MSI-H mCRC | Neoadjuvant/adjuvant chemotherapy | Anti-PD1 ± anti-CTLA-4 or *systemic chemotherapy as recommended above* | Anti-PD1 ± anti-CTLA-4 if no IO given as first line |
| BRAF V600E mCRC | Neoadjuvant/adjuvant chemotherapy | *Systemic chemotherapy as recommended above* | Anti-BRAF + anti-EGFR |
| HER2 | Neoadjuvant/adjuvant chemotherapy | *Systemic chemotherapy as recommended above* | Anti-HER2 therapy  |

\*Adverse events are more common with triplet chemotherapy. *Abbreviations: mCRC = Metastatic colorectal cancer; IO = immunotherapy; pMMR/dMMR = Proficient mismatch repair/Deficient mismatch repair; MSS/MSI-H = Microsatellite stable/Microsatellite instability – high.*

**Table 3.** Regional Therapy Regimens for Metastatic Colorectal Cancer

with Peritoneal Involvement.

|  |  |
| --- | --- |
| Regional Regimens | Currently in use/under investigation |
| HIPEC | Mitomycin C (preferred)Oxaliplatin  |
| PIPAC | Multiple anti-neoplastic agents are being tested  |
| EPIC | Floxuridine |
| IP | Cellular therapies, immunotherapy, STING agonists |

*Abbreviations: HIPEC = Hyperthermic (heated) intraperitoneal chemotherapy;*

*PIPAC = Pressurized intraperitoneal aerosolized chemotherapy; EPIC = Early*

*postoperative intraperitoneal chemotherapy; IP = Intraperitoneal; STING =*

*Stimulation of Transcription factor-1-Interacting Protein 5.*

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| First Author, Year(Country) | Population | Systemic Therapy Regimens | Systemic Therapy Sequence; Duration | Comparison | Sample Size | Peritoneal Cancer Index (PCI, median); Completeness of cytoreduction (CC) or Residual tumor classification (R) | Follow-up Duration | Overall Survival (months); Hazard ratio (95% Confidence Interval) | Major Adverse Events\* |
| Beal, 20201(USA) | Patients with CRC-PM undergoing CRS-HIPEC | FOLFOX, FOLFIRI, bev, capecitabine, XELOX, 5-FU + leucovorin | NAC and/or AC; duration not specified | NAC vs. no NAC (Upfront CRS) | 298  | 12.1; CC0: 74.0%, CC1: 15.8% | NR | NAC 32.7m vs. no NAC 22.0m; Adjusted HR 0.8 (95% CI 0.5-1.2) | 35.9% |
| Cashin, 20232(International) | Patients with CRC-PM undergoing CRS-HIPEC | FOLFOX, FOLFIRI, bev, capecitabine, XELOX, 5-FU + leucovorin | NAC and/or AC; duration not specified  | NAC vs. no NAC (upfront CRS), AC vs. no AC; Propensity score matching used | 2,093 | 10.1; CC0: 93%, CC1: 5% | 10 years | NAC 34.7m vs. no NAC 37.0m; HR 1.08 (95% CI 0.88-1.32); AC 45.7m vs. no AC 37.0m; HR 0.79 (95% CI 0.64-.97) | 33% |
| Ceelen, 20143(Belgium) | Patients with CRC-PM undergoing CRS-HIPEC | FOLFOX, FOLFIRI, bev | NAC and/or AC; NAC ≥ 3 months | NAC w/ Bev vs. NAC w/o Bev vs. no NAC | 166 | 4†; CC0: 47.6%, CC1: 39.8% | 18 months | NAC w/ Bev 39m vs. NAC w/o Bev 22m vs. no NAC 25m; Adjusted HR NAC w/Bev = 0.31 (95% CI 0.12-0.83) | 35% |
| Devilee, 20164(Netherlands) | Patients with CRC-PM undergoing CRS-HIPEC | Capecitabine, CAPOX, CAPOX + bev, FOLFOX | NAC or AC; duration not specified | NAC vs. AC  | 91 | 6; CC0: 96%, CC1: 4% | 28 months | NAC not reached vs. AC 38.6m; Adjusted HR 0.23 (95% CI 0.07-075) | 18.7% |
| Hanna, 20235(USA) | Patients with CRC-PM undergoing CRS-HIPEC | FOLFOX ± bev, FOLFIRI ± bev, CAPOX | NAC 6 months or NAC + AC (Sandwich); 6 months  | NAC vs. Sandwich | 79 | 11.4; CC0: 85.3%, CC1: 8.8% | NR | NAC 77m vs. Sandwich 61m; Adjusted HR 0.96 (95% CI 0.45-1.32) | NR |
| Kuijpers, 20146(Netherlands) | Lymph node-positive CRC patients with PM undergoing CRS-HIPEC | FOLFOX, FOLFIRI, bev, capecitabine, XELOX, 5-FU + leucovorin | NAC and/or AC; duration not specified  | Any periop chemo vs. no chemo  | 73 | 5†; ^R1: 87%, R2a: 13% | 47 months | Any chemo 30m vs. no chemo 14m#; No significant differences based on chemo sequence (NAC/AC) | 30.1% |
| Maillet, 20167(France) | Patients with isolated CRC-PM undergoing CRS-HIPEC  | FOLFOX, FOLFIRI, bev, cetuximab | NAC and/or AC; duration not specified  | AC vs. no AC  | 221 | NR; CC0: 100% | 34 months | AC 49 m vs. no AC 43 months; Adjusted HR 1.13 (95% CI 0.7-1.84) | 44.8% |
| Noda, 20238(Japan) | Patients with CRC-PM undergoing CRS-HIPEC | 5-FU-based ± oxaliplatin ± irinotecan | NAC and/or AC; duration not specified  | AC vs. no AC | 123 | NR; R0: 26%, R1: 13.8%, R2: 59.3% | NR | 5-year OS rate R0/1 subgroup = AC 48.2% vs. no AC 38.1%; Adjusted HR 0.366 (95% CI 0.137-0.997) | 21.1% |
| Repullo, 20219(Belgium) | Patients with CRC-PM with PCI<25 undergoing CRS-HIPEC | FOLFOX or FOLFIRI ± cetuximab or bev | Periop - within 3 months pre/post CRS; ≥ 5 cycles | Periop chemo vs. no chemo | 125 | 6; R0/R1: 100% | 54 months  | Chemo 43m vs. no chemo 72m; Adjusted HR 1.46 (95% CI 0.87-2.47) | 21.6% |
| Sugarbaker, 202210(USA) | Lymph node-positive CRC patients with isolated PM undergoing CRS-HIPEC/EPIC | Not specified  | NAC and/or AC; duration not specified | NAC vs. no NAC (Upfront CRS) | 73 | 13; CC0/CC1: 100% | NR | NAC 2.3y vs no NAC 2.9y; HR 1.00 (95% CI 0.62-1.68) | 33.4% |
| Van Eden, 201711(Netherlands) | Patients with CRC-PM undergoing CRS-HIPEC  | CAPOX or FOLFOX or not specified  | NAC within 4 months/periop; AC within 3 months | NAC/periop vs. AC vs. chemo only before PC diagnosis (earlier chemo) | 280 | Range: 0-7†; R0/R1: 91%, R2a: 8.1% | 29.8 months | NAC/periop 36.9m vs. AC 43.1m vs. earlier chemo 34.0m; Adjusted HR NAC/periop vs. AC 0.84 (95% CI 0.53-1.35) | 30.0% |
| Zhou, 202112(China) | Patients with CRC-PM undergoing CRS-HIPEC | XELOX or FOLFOX or FOLFIRI ± bev, 5-FU + leucovorin | NAC > 3 cycles &/or AC; duration not specified | NAC vs. no NAC (Upfront surgery) | 52 | 11.9; CC0/CC1: 59.6%, CC2/3: 40.4% | 18.5 months | 2-year OS rate = NAC 67.4% vs. no NAC 32.2%; Adjusted HR 0.55 (95% CI 0.22-1.39) | 34.6% |
| Rovers, 202013(Netherlands) | Patients with isolated CRC-PM undergoing CRS-HIPEC | CAPOX or FOLFOX or 5-FU or capecitabine or not specified  | No NAC (Upfront CRS) ± AC; AC within 3 months | AC vs. no AC (active surveillance); Propensity score matching used | 393 | NR; CC0/CC1: 100% | 25.9 months | AC 39.2m VS. no AC 24.8m; HR 0.66 (95% CI 0.49-0.88) |  |

**Table 4.** Key Question 1: In patients with CRC-PM undergoing CRS, what are the optimal sequences and regimens of systemic therapy (neoadjuvant, adjuvant, perioperative)?

*\*Major adverse events = Defined variably across studies between Clavien-Dindo/CTCAE 2 through 5; †Uses regional score and not PCI; ^R1 = No residual macroscopic tumor, R2a = Macroscopic residual tumor* $<$*2.5 mm; #Difference attenuated when accounting for major postoperative complications (associated with reduced likelihood of receiving AC). Abbreviations: NR = not reported; CRC-PM = colorectal cancer with peritoneal metastases; CRLM = colorectal liver metastases; CRS = cytoreductive surgery; HIPEC = heated intraperitoneal chemotherapy; CC = completeness of cytoreduction; R = residual tumor classification; Bev = bevacizumab; 5-FU = 5-fluorouracil; ctDNA = circulating tumor DNA; cfDNA = cell-free DNA; PCI = peritoneal cancer index; NAC = neoadjuvant chemotherapy; AC = adjuvant chemotherapy; OS = overall survival; Sandwich = neoadjuvant and adjuvant chemotherapy; HR = Hazard ratio; CI = Confidence interval; Periop = Perioperative; Chemo = Chemotherapy.*

**Table 5.** Key Question 2a: In patients with CRC-PM, does plasma-based liquid biopsy offer better sensitivity, specificity, and lead time therapy compared with standard surveillance modalities in detecting recurrence following CRS?

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **First Author, Year (Country)** | **Population**  | **Index Test**  | **Index Test Timing**  | **Sample Size**  | **PM**  | **OUTCOMES**  |
| **Preoperative ctDNA**  | **Postoperative ctDNA**  | **Sites or Recurrence**  | **ctDNA vs. CEA**  |
| Beagan, 202014 (Netherlands)  | CRC-PM ± limited LMs  | Tumor-informed cfDNA  | Preop and ≥ 1 postop, then every 3 months for 2 years  | 30 (24 CRS-HIPEC)  | 100%  | Detectable in 33% (8/24) pts; A/w Inferior RFS vs. undetectable ctDNA- HR 3.5 (95% CI 1.1-10.4)  | Available for 19 pts - Sn 38% (5/13) and Sp 100% (6/6) for recurrence  | Lower Sn of ctDNA for locoregional vs. systemic recurrence (1/8 vs. 4/5)  | NR   |
| #Baumgartner, 201815(USA)  | PM (multiple primaries)  | Tumor agnostic ctDNA (Guardant)  | Between 1-2 weeks preop, no postop  | 80 (11 CRC)  | 100%  | Detectable in 39% (31/80) pts; \*High ctDNA A/w inferior PFS- HR 2.4 (95% CI 1.02-5.45)  | NR  | NR  | NR  |
| #Baumgartner, 202016(USA)  | PM (multiple primaries)  | Tumor agnostic ctDNA (Guardant)  | 1-2 weeks preop and 2-5 weeks postop  | 71 (16 CRC)  | 100%  | Detectable in 39% (28/71) overall pts, 62.3% (10/16) CRC pts; \*High ctDNA A/w inferior PFS- HR 3.0 (95% CI 1.6-6.0)  | Detectable in 52% (38) overall pts, 63% (10/16) CRC pts; \*High ctDNA A/w inferior PFS: HR 2.2 (CI 1.1-4.2)  | NR  | NR  |
| #Dhiman, 202317 (USA)  | CRC and high-grade AC with PM  | Tumor-informed ctDNA (Signatera)  | Every 3 months for one year postop  | 33 (13 CRC)  | 100%  | NR  | Rising ctDNA A/w inferior DFS vs. undetectable ctDNA- HR 3.7 (95% CI 1.1-12.7); Rising ctDNA Sn 85.0% (17/20) and Sp 84.6% (11/13) for recurrence  | Systemic recurrence A/w higher ctDNA levels vs. peritoneal-only recurrence (199.3 vs. 0.9 MTM/ml)  | ctDNA more Sn than CEA (85% vs. 50%) for recurrence  |
| Hofste, 202318 (Netherlands)  | Metastatic CRC (multiple sites)  | Tumor-informed ctDNA  | Preop on the day of surgery and 1 week postop  | 53  | 11.30%  | Detectable in 81% (43/53) pts  | Available for 16 pts - Detectable in 25% (4/16) pts  | LM A/w higher preop ctDNA detection rate (84% vs. 33%) and ctDNA levels (125.3 vs. 3.3 MTM/ml) compared to PM  | Preop ctDNA levels correlated with tumor burden, CEA levels did not |
| Lopez-Rojo, 202019 (Spain)  | KRAS-mutated CRC and AC with PM/risk for PM  | ddPCR for KRAS mutations in ctDNA  | Preop and 48 hours postop  | 11 (7 CRC^)  | 55%  | Detectable in 71% (5/7) CRC pts - Sn 80% (4/5) and Sp 50% (1/2) for recurrence  | Available for 5 CRC pts, detectable in 80% (4) pts – Sn 100% (4/4) and Sp 100% (1/1) for recurrence  | NR  | NR  |
| Loupakis, 202120 (Italy)  | Metastatic CRC (multiple sites)  | Tumor-informed ctDNA (Signatera)  | Within 4 weeks postop & at progression or last follow-up  | 112  | 14.20%  | NR  | ctDNA detection (MRD) in 54% (61/112) of pts – Sn 72% (59/82) and Sp 93% (28/30) for recurrence; MRD A/w inferior DFS - HR 5.8 (95% CI 3.3-10.0)  | NR  | MRD A/w inferior DFS, CEA not associated –  HR 1.5 (95% CI 0.8-2.7)  |

*#Baumgartner 2018, Baumgartner 2020, and Dhiman 2023 do not report CRC-specific outcomes; ^HIPEC indication in 7 CRC pts = carcinomatosis (4) and second look for high-risk CRC (3); \*High ctDNA levels = MSVAF ≥ 0.25%. Abbreviations: NR= not reported; CRC = Colorectal cancer; PM = Peritoneal metastases; LM = Liver metastases; cfDNA = cell free DNA; ctDNA = circulating tumor DNA; CEA = Carcinoembryonic antigen; CRS = Cytoreductive surgery; HIPEC = Hyperthermic intraperitoneal chemotherapy; Preop = Preoperatively; Postop = Postoperatively; A/w = Associated with; RFS = Recurrence free survival; PFS = Progression free survival; DFS = Disease free survival; HR = Hazard ratio; CI = Confidence interval; Sn = Sensitivity; Sp = Specificity; MTM = Mean tumor molecules; MSVAF = Maximum somatic variant allele fraction; MRD = Minimal or molecular residual disease; ddPCR = digital droplet Polymerase Chain Reaction.*

**REFERENCES**

1 Beal, E. W. *et al.* Impact of Neoadjuvant Chemotherapy on the Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Multi-Institutional Retrospective Review. *J Clin Med* **9** (2020). <https://doi.org:10.3390/jcm9030748>

2 Cashin, P. H. *et al.* Perioperative chemotherapy in colorectal cancer with peritoneal metastases: A global propensity score matched study. *EClinicalMedicine* **55**, 101746 (2023). <https://doi.org:10.1016/j.eclinm.2022.101746>

3 Ceelen, W., Van Nieuwenhove, Y., Putte, D. V. & Pattyn, P. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis. *Ann Surg Oncol* **21**, 3023-3028 (2014). <https://doi.org:10.1245/s10434-014-3713-7>

4 Devilee, R. A. *et al.* Increased Survival of Patients with Synchronous Colorectal Peritoneal Metastases Receiving Preoperative Chemotherapy Before Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. *Ann Surg Oncol* **23**, 2841-2848 (2016). <https://doi.org:10.1245/s10434-016-5214-3>

5 Hanna, D. N. *et al.* A total neoadjuvant chemotherapy approach is associated with improved recurrence-free survival in patients with colorectal peritoneal metastases undergoing cytoreductive surgery and HIPEC. *J Surg Oncol* **127**, 442-449 (2023). <https://doi.org:10.1002/jso.27136>

6 Kuijpers, A. M. *et al.* Perioperative systemic chemotherapy in peritoneal carcinomatosis of lymph node positive colorectal cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *Ann Oncol* **25**, 864-869 (2014). <https://doi.org:10.1093/annonc/mdu031>

7 Maillet, M. *et al.* Early Postoperative Chemotherapy After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Isolated Peritoneal Carcinomatosis of Colon Cancer: A Multicenter Study. *Ann Surg Oncol* **23**, 863-869 (2016). <https://doi.org:10.1245/s10434-015-4914-4>

8 Noda, K. *et al.* Effect of adjuvant chemotherapy after curative resection of colorectal cancer peritoneal metastasis. *Int J Colorectal Dis* **38**, 101 (2023). <https://doi.org:10.1007/s00384-023-04407-8>

9 Repullo, D. J. *et al.* The absence of benefit of perioperative chemotherapy in initially resectable peritoneal metastases of colorectal cancer origin treated with complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A retrospective analysis. *Eur J Surg Oncol* **47**, 1661-1667 (2021). <https://doi.org:10.1016/j.ejso.2021.01.018>

10 Sugarbaker, P. H. & Chang, D. Revised prognostic indicators for treatment of lymph node positive colorectal peritoneal metastases. *J Surg Oncol* **125**, 889-900 (2022). <https://doi.org:10.1002/jso.26792>

11 van Eden, W. J. *et al.* Timing of Systemic Chemotherapy in Patients With Colorectal Peritoneal Carcinomatosis Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. *Dis Colon Rectum* **60**, 477-487 (2017). <https://doi.org:10.1097/DCR.0000000000000774>

12 Zhou, S. *et al.* High-grade postoperative complications affect survival outcomes of patients with colorectal Cancer peritoneal metastases treated with Cytoreductive surgery and Hyperthermic Intraperitoneal chemotherapy. *BMC Cancer* **21**, 41 (2021). <https://doi.org:10.1186/s12885-020-07756-7>

13 Rovers, K. P. *et al.* Adjuvant Systemic Chemotherapy vs Active Surveillance Following Up-front Resection of Isolated Synchronous Colorectal Peritoneal Metastases. *JAMA Oncol* **6**, e202701 (2020). <https://doi.org:10.1001/jamaoncol.2020.2701>

14 Beagan, J. J. *et al.* Circulating Tumor DNA as a Preoperative Marker of Recurrence in Patients with Peritoneal Metastases of Colorectal Cancer: A Clinical Feasibility Study. *J Clin Med* **9** (2020). <https://doi.org:10.3390/jcm9061738>

15 Baumgartner, J. M. *et al.* Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival. *Ann Surg Oncol* **25**, 2400-2408 (2018). <https://doi.org:10.1245/s10434-018-6561-z>

16 Baumgartner, J. M. *et al.* Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases. *Ann Surg Oncol* **27**, 3259-3267 (2020). <https://doi.org:10.1245/s10434-020-08331-x>

17 Dhiman, A. *et al.* Role of Tumor-informed Personalized Circulating Tumor DNA Assay in Informing Recurrence in Patients With Peritoneal Metastases From Colorectal and High-grade Appendix Cancer Undergoing Curative-intent Surgery. *Ann Surg* **278**, 925-931 (2023). <https://doi.org:10.1097/SLA.0000000000005856>

18 Hofste, L. S. M. *et al.* Clinical Validity of Tumor-Informed Circulating Tumor DNA Analysis in Patients Undergoing Surgery of Colorectal Metastases. *Dis Colon Rectum* **66**, 796-804 (2023). <https://doi.org:10.1097/DCR.0000000000002443>

19 Lopez-Rojo, I. *et al.* Liquid biopsy in peritoneal fluid and plasma as a prognostic factor in advanced colorectal and appendiceal tumors after complete cytoreduction and hyperthermic intraperitoneal chemotherapy. *Ther Adv Med Oncol* **12**, 1758835920981351 (2020). <https://doi.org:10.1177/1758835920981351>

20 Loupakis, F. *et al.* Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases. *JCO Precis Oncol* **5** (2021). <https://doi.org:10.1200/PO.21.00101>